Olink Holding Ab (Publ) Stock Price, News & Analysis

The shareholders of Olink Holding AB are invited to the Annual General Meeting on April 7, 2022, at 4:00 p.m. CET in Uppsala, Sweden. Registration starts at 3:30 p.m. Shareholders must be recorded in the share register by March 30, 2022, and notify the company by April 1, 2022, to participate. The agenda includes the election of the Board of Directors, approval of financial statements, and proposals for incentive programs for board members. Notably, the meeting will allow electronic participation subject to approval. The meeting also addresses the proposed issuance of stock options and other incentives.

Olink Holding AB reported strong financial results for Q4 and the full year 2021, achieving $43.7 million in quarterly revenue, a 61% increase year-over-year. Full-year revenue hit $95.0 million, up 76%. The company plans for revenue guidance of $138 million to $145 million in 2022, reflecting a growth rate of 45% to 53%. The net loss for the fourth quarter was ($8.0) million, compared to a profit of $6.5 million in the prior year. Adjusted EBITDA was (1.4) million for Q4. Olink anticipates continued investment in its proteomics platform to drive further growth.

Olink Holding AB (Nasdaq: OLK) announced participation in two virtual investor conferences. Jon Heimer, CEO, and Oskar Hjelm, CFO, will represent the company at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 15 at 8:30 am ET and the 11th Annual SVB Leerink Global Healthcare Conference on February 18 at 8:40 am ET. The SVB Leerink conference will feature a live and archived webcast available on Olink's website. Olink is committed to advancing proteomics to foster healthcare breakthroughs.

Olink Holding AB (Nasdaq: OLK) partners with Sequanta Technologies to apply its Olink® Explore 3072 platform in analyzing 1,000 patient samples from a cohort study in China. This collaboration, which began in 2021, allows Sequanta to utilize Olink's Proximity Extension Assay technology for multi-omic clinical studies, driving advancements in precision medicine. Sequanta has reported significant local demand, resulting in multiple contracts with esteemed research institutions and pharmaceutical firms in China. Olink aims to expand its protein biomarker library through this partnership, targeting the growing proteomics market.

Olink Holding AB (Nasdaq: OLK) reported preliminary fourth quarter and full year 2021 revenues, estimating Q4 revenues between $43.2 million and $43.7 million, up from $27.2 million in Q4 2020. Full year revenues are expected between $94.5 million and $95.0 million, reflecting a 75% increase year-over-year. The kit share of total revenues for Q4 is expected at 35%, compared to 18% in Q3 2021. Olink plans to provide 2022 guidance on February 14, 2022, during their earnings call.

Olink Holding AB (Nasdaq: OLK) will participate in the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 9:00 am ET. CEO Jon Heimer is scheduled to present, with a live and archived webcast available on the company’s website. Olink focuses on accelerating proteomics to enable new scientific discoveries and improve patient outcomes. Founded in 2016, Olink is established in Europe, North America, and Asia, providing products and services for biopharmaceutical companies and academic institutions.

Olink Holding AB (Nasdaq: OLK) has announced a new peer-reviewed publication detailing its Proximity Extension Assay (PEA) technology, now integrated with Next Generation Sequencing (NGS). This publication serves as a critical resource for the scientific community, highlighting the Olink Explore platform's capacity to measure nearly 3000 proteins simultaneously. The technology aims to enhance biomarker discovery for disease prediction and monitoring, ensuring higher assay sensitivity and throughput. Since its launch, this platform has significantly influenced several disease studies, generating an increasing number of citations from researchers.

Olink Holding AB (Nasdaq: OLK) announced that its collaboration with Boehringer Ingelheim on protein biomarkers in the empagliflozin EMPEROR studies has entered the data analysis phase. Empagliflozin (JARDIANCE) has shown promise in lowering cardiovascular death risks in type 2 diabetes patients. The analysis aims to enhance understanding of drug mechanisms and improve patient stratification, utilizing blood samples from 3,000 heart failure patients. This effort represents a significant proteomics analysis targeting an approved drug, potentially setting a precedent in pharmacodynamics research.

Olink Holding AB (Nasdaq: OLK) has initiated delivery of the new Olink® Explore 3072, which features an expanded library of approximately 3000 validated assays. This platform allows for increased throughput, processing over 4600 samples weekly while measuring nearly 3000 proteins per sample. The Olink® Explore 3072 enhances the dynamic range of protein measurements, crucial for biomarkers like PSA for prostate cancer. CEO Jon Heimer highlighted that the Explore platform accounted for over 60% of Q3 business, reflecting growing customer interest and scientific impact, with over 750 peer-reviewed publications citing their technology.